Sector ratings Altimmune, Inc.

Equities

Market Closed - Nasdaq Other stock markets 16:00:00 2026-01-20 EST			5-day change	1st Jan Change
4.230 ^USD	-0.24%		+5.49%	+17.17%

01-05	Altimmune, Inc. Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH	CI
01-05	Altimmune Says US FDA Grants Breakthrough Therapy Designation for Pemvidutide in MASH	MT

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Financial revisions	Global Valuation	Visibility	Consensus
ALTIMMUNE, INC.	462M	-	BBB	-		-
ARGENX SE	49.24B		AA
WUXI APPTEC CO., LTD.	42.5B		AAA
INSMED INCORPORATED	34.87B	-	BBB	-		-
BIONTECH SE	26.49B	-	-	-		-
WUXI BIOLOGICS (CAYMAN) INC.	19.66B		AAA
GENMAB A/S	19.33B		AA
AKESO, INC.	13.89B		B			-
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	13.23B	-	A	-		-
SUMMIT THERAPEUTICS INC.	12.38B	-	-	-		-
MYOKARDIA, INC.	11.99B	-	-	-	-	-	-	-
EXELIXIS, INC.	11.79B		BB
MADRIGAL PHARMACEUTICALS, INC.	11.47B	-	B	-		-
ACCELERON PHARMA INC.	10.93B	-	-	-	-	-	-	-
SAMSUNG EPIS HOLDINGS CO., LTD.	10.65B	-	-	-	-	-	-	-
ARROWHEAD PHARMACEUTICALS, INC.	8.97B	-	BBB	-		-
CEREVEL THERAPEUTICS HOLDINGS, INC.	8.19B	-	-	-	-	-	-	-
NUVALENT, INC.	8.23B	-	CCC	-		-
REMEGEN CO., LTD.	7.71B		-			-
CYTOKINETICS, INCORPORATED	7.8B	-	AA	-		-
Average	16.49B		A
Weighted average by Cap.			A